Barbara Gunsenheimer-Bartmeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Barbara Gunsenheimer-Bartmeyer has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Viviane Bremer
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
10 shared publications - Uwe Koppe
Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
7 shared publications - Osamah Hamouda
Department for Infectious Disease Epidemiology, Division for HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany
5 shared publications - Stefan Albrecht
Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany
5 shared publications - Ulrich Marcus
Department of Infectious Disease Epidemiology, Robert Koch-Institute, Berlin, Germany
5 shared publications - Jens Hoebel
Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany
4 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Analysis of potential barriers for PrEP non-users among PrEP-eligible MSM in Germany
Background: Daily oral pre-exposure prophylaxis (PrEP) provides effective protection against HIV. Since September 2019, the costs of PrEP have been covered by statutory health insurance in Germany. While a considerable fraction of PrEP-eligible individuals receives PrEP, coverage is inhomogeneous across Germany. This study aims to identify potential barriers associated with PrEP non-use among PrEP-eligible MSM. Methods: Based on the PrApp online cross-sectional study, we analyzed 1,027 PrEP users and 431 PrEP non-users. A PrEP indication was assumed for cis-MSM with a diagnosis of a bacterial STI (syphilis, gonorrhea, chlamydia) or hepatitis C (12 months), ≥ 2 sex partners or sexualized drug use (6 months). Characteristics between PrEP users and PrEP non-users were compared descriptively and using multivariable logistic regression. Results: PrEP non-users were more likely to be aged 18–29 years old ( P < 0.05, reference group: 30–39 years) and to engage in sexualized drug use ( P < 0.001). The highest HIV-specialists density ( P < 0.01, reference group: 6–9 HIV-specialists per 10,000 gay men) was associated with PrEP use. Persons with sexualized drug use were more likely to report daily PrEP use as a barrier (34.3% vs. 16.9%, adjusted P < 0.05). Fear of side effects (54.5%) was the most common barrier and might be more pronounced in PrEP non-users living in a federal state with a high HIV-specialists density (67.9% vs. 51.8%, adjusted P = 0.08). PrEP non-users living in a federal state with a low HIV-specialists density described not wanting to discuss their sex life with their doctor (29.5% vs. 16.0%, adjusted P = 0.08) as a reason for PrEP non-use. Conclusions: Our analyses indicated structural barriers to PrEP use in federal states with a low HIV-specialists density (physician density, non-anonymity). For those with theoretical PrEP access (high HIV-specialists density), fear of side effects could potentially be addressed by effective risk communication.
- 27 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Open AccessAnalysis of potential barriers for PrEP non-users among PrEP-eligible MSM in Germany
Background: Daily oral pre-exposure prophylaxis (PrEP) provides effective protection against HIV. Since September 2019, the costs of PrEP have been covered by statutory health insurance in Germany. While a considerable fraction of PrEP-eligible individuals receives PrEP, coverage is inhomogeneous across Germany. This study aims to identify potential barriers associated with PrEP non-use among PrEP-eligible MSM. Methods: Based on the PrApp online cross-sectional study, we analyzed 1,027 PrEP users and 431 PrEP non-users. A PrEP indication was assumed for cis-MSM with a diagnosis of a bacterial STI (syphilis, gonorrhea, chlamydia) or hepatitis C (12 months), ≥ 2 sex partners or sexualized drug use (6 months). Characteristics between PrEP users and PrEP non-users were compared descriptively and using multivariable logistic regression. Results: PrEP non-users were more likely to be aged 18–29 years old ( P < 0.05, reference group: 30–39 years) and to engage in sexualized drug use ( P < 0.001). The highest HIV-specialists density ( P < 0.01, reference group: 6–9 HIV-specialists per 10,000 gay men) was associated with PrEP use. Persons with sexualized drug use were more likely to report daily PrEP use as a barrier (34.3% vs. 16.9%, adjusted P < 0.05). Fear of side effects (54.5%) was the most common barrier and might be more pronounced in PrEP non-users living in a federal state with a high HIV-specialists density (67.9% vs. 51.8%, adjusted P = 0.08). PrEP non-users living in a federal state with a low HIV-specialists density described not wanting to discuss their sex life with their doctor (29.5% vs. 16.0%, adjusted P = 0.08) as a reason for PrEP non-use. Conclusions: Our analyses indicated structural barriers to PrEP use in federal states with a low HIV-specialists density (physician density, non-anonymity). For those with theoretical PrEP access (high HIV-specialists density), fear of side effects could potentially be addressed by effective risk communication.
- Open Access
- 28 February 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
The potential of routine surveillance data for identifying the needs of people living with HIV among migrants: Description of German HIV notifications in the context of the Ukrainian refugee reception, 2022–2023
Background: Since the start of Russia’s war against Ukraine, more than one million people from Ukraine – a country with high Human Immunodeficiency Virus (HIV)-prevalence – have fled to Germany. We aimed to estimate the number of people living with HIV (PLHIV) with a link to Ukraine reported to the German HIV notification system, analyse their characteristics and estimate the proportion of prior known infections to better understand the care needs of this population. Methods: We descriptively analysed HIV surveillance data from 2001 to 2023 regarding links to Ukraine. We further characterised HIV notifications received between March 2022 and December 2023 with either a link to Ukraine or Germany in terms of reported transmission routes, age and gender distributions. We estimated the proportions of prior known and probably prior known diagnoses based on notifier comments, reported CD4 cell count and viral load measurements. Results: We found a steep increase in Ukraine-linked notifications starting in March 2022, with yearly proportions reaching 19.7% in 2022 and 13.1% in 2023, compared to only 0.2%-1.6% in previous years. Among PLHIV from Ukraine, most were female (60%), and the majority of adult cases reported heterosexual transmission (74%). In contrast, notifications linked to Germany predominantly involved men who have sex with men (MSM) (45%). Compared to notifications about PLHIV linked to Germany, those about PLHIV associated to Ukraine showed a higher proportion of children (5% vs. 2%) – the majority of whom were infected through pre- and perinatal transmission (89%). The majority of PLHIV from Ukraine had either prior known or probably prior known diagnoses (53% of adults, 75% of children). Conclusions: Thus, PLHIV from Ukraine differ in their characteristics from those linked to Germany and consequently in their needs regarding HIV prevention and care services. They require rapid access to healthcare structures in Germany to ensure continuity of treatment. Our findings highlight the importance of considering migrant and refugee populations within Germany’s national HIV strategies, which are currently focused primarily on MSM. While our results demonstrate the overall usefulness of HIV surveillance data for characterising migrant populations, they also call for improvements in data quality and completeness.
- 28 February 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Open AccessThe potential of routine surveillance data for identifying the needs of people living with HIV among migrants: Description of German HIV notifications in the context of the Ukrainian refugee reception, 2022–2023
Background: Since the start of Russia’s war against Ukraine, more than one million people from Ukraine – a country with high Human Immunodeficiency Virus (HIV)-prevalence – have fled to Germany. We aimed to estimate the number of people living with HIV (PLHIV) with a link to Ukraine reported to the German HIV notification system, analyse their characteristics and estimate the proportion of prior known infections to better understand the care needs of this population. Methods: We descriptively analysed HIV surveillance data from 2001 to 2023 regarding links to Ukraine. We further characterised HIV notifications received between March 2022 and December 2023 with either a link to Ukraine or Germany in terms of reported transmission routes, age and gender distributions. We estimated the proportions of prior known and probably prior known diagnoses based on notifier comments, reported CD4 cell count and viral load measurements. Results: We found a steep increase in Ukraine-linked notifications starting in March 2022, with yearly proportions reaching 19.7% in 2022 and 13.1% in 2023, compared to only 0.2%-1.6% in previous years. Among PLHIV from Ukraine, most were female (60%), and the majority of adult cases reported heterosexual transmission (74%). In contrast, notifications linked to Germany predominantly involved men who have sex with men (MSM) (45%). Compared to notifications about PLHIV linked to Germany, those about PLHIV associated to Ukraine showed a higher proportion of children (5% vs. 2%) – the majority of whom were infected through pre- and perinatal transmission (89%). The majority of PLHIV from Ukraine had either prior known or probably prior known diagnoses (53% of adults, 75% of children). Conclusions: Thus, PLHIV from Ukraine differ in their characteristics from those linked to Germany and consequently in their needs regarding HIV prevention and care services. They require rapid access to healthcare structures in Germany to ensure continuity of treatment. Our findings highlight the importance of considering migrant and refugee populations within Germany’s national HIV strategies, which are currently focused primarily on MSM. While our results demonstrate the overall usefulness of HIV surveillance data for characterising migrant populations, they also call for improvements in data quality and completeness.
- Open Access
- 1 December 2025
- Published by Springer Nature in Research Square
Analysis of potential barriers for non-PrEP users among MSM in Germany
Background. Daily oral pre-exposure prophylaxis (PrEP) provides effective protection against HIV. Since September 2019, the costs of PrEP have been reimbursed by statutory health insurance in Germany. While a considerable fraction of PrEP-eligible individuals receives PrEP, coverage is inhomogeneous across Germany. This study aims to identify potential barriers associated with PrEP non-use. Methods. Based on the PrApp online cross-sectional study, we analyzed 1,027 PrEP users and 431 non-PrEP users. A PrEP indication was assumed for cis-MSM with an STI diagnosis (12 months), ≥ 2 sex partners or sexualized drug use (6 months). Characteristics between PrEP users and PrEP non-users were compared descriptively and using multivariable logistic regression. Results. Non-PrEP users were more likely to be aged 18-29 years old (P < 0.05) and to use drugs during sex (P < 0.01). The highest HIV-specialists density (P < 0.01) was associated with PrEP use. Fear of side effects (54.5%) was the most common barrier and more pronounced in non-PrEP users living in a federal state with a high HIV-specialists density (67.9% vs. 51.8%) as well as low HIV-risk perception (35.8% vs. 24.1%). Non-PrEP users living in a federal state with a low HIV-specialists density described not wanting to discuss their sex life with their doctor (29.5% vs. 16.0%) as a reason for PrEP non-use. Persons with sexualized drug use were more likely to report daily PrEP use as a barrier (34.3% vs. 16.9%, P < 0.01, adjusted P < 0.05). Conclusions. Our analyses indicated structural barriers to PrEP use in federal states with a low HIV-specialists density (physician density, non-anonymity). For those with theoretical PrEP access (high HIV-specialists density), underestimation of HIV risk and fear of side effects could potentially be overcome by effective risk communication.
- 1 December 2025
- Published by Springer Nature in Research Square
Open AccessAnalysis of potential barriers for non-PrEP users among MSM in Germany
Background. Daily oral pre-exposure prophylaxis (PrEP) provides effective protection against HIV. Since September 2019, the costs of PrEP have been reimbursed by statutory health insurance in Germany. While a considerable fraction of PrEP-eligible individuals receives PrEP, coverage is inhomogeneous across Germany. This study aims to identify potential barriers associated with PrEP non-use. Methods. Based on the PrApp online cross-sectional study, we analyzed 1,027 PrEP users and 431 non-PrEP users. A PrEP indication was assumed for cis-MSM with an STI diagnosis (12 months), ≥ 2 sex partners or sexualized drug use (6 months). Characteristics between PrEP users and PrEP non-users were compared descriptively and using multivariable logistic regression. Results. Non-PrEP users were more likely to be aged 18-29 years old (P < 0.05) and to use drugs during sex (P < 0.01). The highest HIV-specialists density (P < 0.01) was associated with PrEP use. Fear of side effects (54.5%) was the most common barrier and more pronounced in non-PrEP users living in a federal state with a high HIV-specialists density (67.9% vs. 51.8%) as well as low HIV-risk perception (35.8% vs. 24.1%). Non-PrEP users living in a federal state with a low HIV-specialists density described not wanting to discuss their sex life with their doctor (29.5% vs. 16.0%) as a reason for PrEP non-use. Persons with sexualized drug use were more likely to report daily PrEP use as a barrier (34.3% vs. 16.9%, P < 0.01, adjusted P < 0.05). Conclusions. Our analyses indicated structural barriers to PrEP use in federal states with a low HIV-specialists density (physician density, non-anonymity). For those with theoretical PrEP access (high HIV-specialists density), underestimation of HIV risk and fear of side effects could potentially be overcome by effective risk communication.
- Open Access
Analysis of potential barriers for non-PrEP users among MSM in Germany
Background: Daily oral pre-exposure prophylaxis (PrEP) provides effective protection against HIV. Since September 2019, the costs of PrEP have been reimbursed by statutory health insurance in Germany. While a considerable fraction of PrEP-eligible individuals receives PrEP, coverage is inhomogeneous across Germany. This study aims to identify potential barriers associated with PrEP non-use. Methods: Based on the PrApp online cross-sectional study, we analyzed 1,027 PrEP users and 431 non-PrEP users. A PrEP indication was assumed for cis-MSM with an STI diagnosis (12 months), ≥ 2 sex partners or sexualized drug use (6 months). Characteristics between PrEP users and PrEP non-users were compared descriptively and using multivariable logistic regression. Results: Non-PrEP users were more likely to be aged 18-29 years old ( P < 0.05) and to use drugs during sex ( P < 0.01). The highest PrEP prescriber density ( P < 0.01) was associated with PrEP use. Fear of side effects (54.5%) was the most common barrier. Persons with sexualized drug use were more likely to report daily PrEP use as a barrier (34.3% vs. 16.9%, P < 0.01, adjusted P < 0.05). Conclusions: Our analyses indicated structural barriers to PrEP use in federal states with a low HIV-specialists density. For those engaging in sexualized drug use, daily PrEP uptake could potentially be overcome by long-acting PrEP.
Open AccessAnalysis of potential barriers for non-PrEP users among MSM in Germany
Background: Daily oral pre-exposure prophylaxis (PrEP) provides effective protection against HIV. Since September 2019, the costs of PrEP have been reimbursed by statutory health insurance in Germany. While a considerable fraction of PrEP-eligible individuals receives PrEP, coverage is inhomogeneous across Germany. This study aims to identify potential barriers associated with PrEP non-use. Methods: Based on the PrApp online cross-sectional study, we analyzed 1,027 PrEP users and 431 non-PrEP users. A PrEP indication was assumed for cis-MSM with an STI diagnosis (12 months), ≥ 2 sex partners or sexualized drug use (6 months). Characteristics between PrEP users and PrEP non-users were compared descriptively and using multivariable logistic regression. Results: Non-PrEP users were more likely to be aged 18-29 years old ( P < 0.05) and to use drugs during sex ( P < 0.01). The highest PrEP prescriber density ( P < 0.01) was associated with PrEP use. Fear of side effects (54.5%) was the most common barrier. Persons with sexualized drug use were more likely to report daily PrEP use as a barrier (34.3% vs. 16.9%, P < 0.01, adjusted P < 0.05). Conclusions: Our analyses indicated structural barriers to PrEP use in federal states with a low HIV-specialists density. For those engaging in sexualized drug use, daily PrEP uptake could potentially be overcome by long-acting PrEP.
- Open Access
- 21 February 2024
- Published by Springer Nature in Infection
- Vol. 52 (2) , 637-648
AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999–2018
Purpose: This study examined the characteristics, incidence and prognostic factors of the first AIDS-defining condition developed after more than one year of continuous antiretroviral therapy (ART) among people living with HIV (PLHIV). Methods: We used data from two multicentre observational cohorts of PLHIV in Germany between 1999 and 2018. Our outcome was the first AIDS-defining event that occurred during follow-up after more than one year of continuous ART. Descriptive analyses at ART initiation, at the time of the AIDS event and of the most frequently observed types of AIDS-defining illnesses were performed. We calculated the incidence rate (IR) per 1000 person-years (PY) and used a bootstrap stepwise selection procedure to identify predictors of the outcome. Results: A total of 12,466 PLHIV were included in the analyses. 378 developed the outcome, constituting an overall IR of 5.6 (95% CI 5.1–6.2) AIDS events per 1000 PY. The majority of PLHIV was virally suppressed at the time of the event. Oesophageal candidiasis and wasting syndrome were the most frequently diagnosed AIDS-defining illnesses. We found a low CD4 count at ART initiation, a previous AIDS-defining condition and transmission through intravenous drug use to be meaningful prognostic factors of the outcome. Conclusion: The overall rate of AIDS-defining events among PLHIV under long-term ART was low, highlighting the importance of continuous treatment. PLHIV who started ART with indicators of impaired immune functioning were more susceptible to disease progression, suggesting that the public health response should continue to focus on early and sustained treatment for all PLHIV.
- 21 February 2024
- Published by Springer Nature in Infection
- Vol. 52 (2) , 637-648
Open AccessAIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999–2018
Purpose: This study examined the characteristics, incidence and prognostic factors of the first AIDS-defining condition developed after more than one year of continuous antiretroviral therapy (ART) among people living with HIV (PLHIV). Methods: We used data from two multicentre observational cohorts of PLHIV in Germany between 1999 and 2018. Our outcome was the first AIDS-defining event that occurred during follow-up after more than one year of continuous ART. Descriptive analyses at ART initiation, at the time of the AIDS event and of the most frequently observed types of AIDS-defining illnesses were performed. We calculated the incidence rate (IR) per 1000 person-years (PY) and used a bootstrap stepwise selection procedure to identify predictors of the outcome. Results: A total of 12,466 PLHIV were included in the analyses. 378 developed the outcome, constituting an overall IR of 5.6 (95% CI 5.1–6.2) AIDS events per 1000 PY. The majority of PLHIV was virally suppressed at the time of the event. Oesophageal candidiasis and wasting syndrome were the most frequently diagnosed AIDS-defining illnesses. We found a low CD4 count at ART initiation, a previous AIDS-defining condition and transmission through intravenous drug use to be meaningful prognostic factors of the outcome. Conclusion: The overall rate of AIDS-defining events among PLHIV under long-term ART was low, highlighting the importance of continuous treatment. PLHIV who started ART with indicators of impaired immune functioning were more susceptible to disease progression, suggesting that the public health response should continue to focus on early and sustained treatment for all PLHIV.
- Open Access
- 17 March 2022
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 22 (1) , 1-12
The impact of regional socioeconomic deprivation on the timing of HIV diagnosis: a cross-sectional study in Germany
HIV infections which are diagnosed at advanced stages are associated with significantly poorer health outcomes. In Germany, the proportion of persons living with HIV who are diagnosed at later stages has remained continuously high. This study examined the impact of regional socioeconomic deprivation on the timing of HIV diagnosis. We used data from the national statutory notification of newly diagnosed HIV infections between 2011 and 2018 with further information on the timing of diagnosis determined by the BED-Capture-ELISA test (BED-CEIA) and diagnosing physicians. Data on regional socioeconomic deprivation were derived from the German Index of Socioeconomic Deprivation (GISD). Outcome measures were a non-recent infection based on the BED-CEIA result or an infection at the stage of AIDS. The effect of socioeconomic deprivation on the timing of diagnosis was analysed using multivariable Poisson regression models with cluster-robust error variance. Overall, 67.5% (n = 10,810) of the persons were diagnosed with a non-recent infection and 15.2% (n = 2746) with AIDS. The proportions were higher among persons with heterosexual contact compared to men who have sex with men (MSM) (76.8% non-recent and 14.9% AIDS vs. 61.7% non-recent and 11.4% AIDS). MSM living in highly deprived regions in the countryside (< 100 k residents) were more likely to have a non-recent infection (aPR: 1.16, 95% CI: 1.05–1.28) as well as AIDS (aPR: 1.41, 95% CI: 1.08–1.85) at the time of diagnosis compared to MSM in less deprived regions in the countryside. No differences were observed among MSM from towns (100 k ≤ 1 million residents) or major cities (≥ 1 million residents), and no differences overall in the heterosexual transmission group. An effect of socioeconomic deprivation on the timing of HIV diagnosis was found only in MSM from countryside regions. We suggest that efforts in promoting HIV awareness and regular HIV testing are increased for heterosexual persons irrespective of socioeconomic background, and for MSM with a focus on those living in deprived regions in the countryside.
- 17 March 2022
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 22 (1) , 1-12
Open AccessThe impact of regional socioeconomic deprivation on the timing of HIV diagnosis: a cross-sectional study in Germany
HIV infections which are diagnosed at advanced stages are associated with significantly poorer health outcomes. In Germany, the proportion of persons living with HIV who are diagnosed at later stages has remained continuously high. This study examined the impact of regional socioeconomic deprivation on the timing of HIV diagnosis. We used data from the national statutory notification of newly diagnosed HIV infections between 2011 and 2018 with further information on the timing of diagnosis determined by the BED-Capture-ELISA test (BED-CEIA) and diagnosing physicians. Data on regional socioeconomic deprivation were derived from the German Index of Socioeconomic Deprivation (GISD). Outcome measures were a non-recent infection based on the BED-CEIA result or an infection at the stage of AIDS. The effect of socioeconomic deprivation on the timing of diagnosis was analysed using multivariable Poisson regression models with cluster-robust error variance. Overall, 67.5% (n = 10,810) of the persons were diagnosed with a non-recent infection and 15.2% (n = 2746) with AIDS. The proportions were higher among persons with heterosexual contact compared to men who have sex with men (MSM) (76.8% non-recent and 14.9% AIDS vs. 61.7% non-recent and 11.4% AIDS). MSM living in highly deprived regions in the countryside (< 100 k residents) were more likely to have a non-recent infection (aPR: 1.16, 95% CI: 1.05–1.28) as well as AIDS (aPR: 1.41, 95% CI: 1.08–1.85) at the time of diagnosis compared to MSM in less deprived regions in the countryside. No differences were observed among MSM from towns (100 k ≤ 1 million residents) or major cities (≥ 1 million residents), and no differences overall in the heterosexual transmission group. An effect of socioeconomic deprivation on the timing of HIV diagnosis was found only in MSM from countryside regions. We suggest that efforts in promoting HIV awareness and regular HIV testing are increased for heterosexual persons irrespective of socioeconomic background, and for MSM with a focus on those living in deprived regions in the countryside.
- Open Access
Similar Sexual Behaviour yet Different Outcomes: Comparing Trans and Gender Diverse and Cis PrEP Users in Germany Based on the Outcomes of the PrApp Study
Little knowledge about pre-exposure prophylaxis (PrEP) use in trans and gender diverse (TGD) communities in Germany exists. The PrApp Study collected data on PrEP use and sexual behaviour among PrEP users in Germany. Descriptive methods and logistic regression were used to describe PrEP use among TGD and cis persons. A total of 4350 PrEP users in Germany were included, with 65 (1.5%) identified as TGD. Compared to cis participants, TGD participants were younger (median age 29 vs. 37 years) and more likely to have a lower income (adjusted odds ratio (aOR) = 4.4; 95% confidence interval (CI) = 2.4–8.2) and be born outside Germany (aOR = 2.5; 95% CI = 1.3–4.5). On-demand PrEP use was higher in TGD participants (aOR = 1.9; 95% CI = 1.0–3.5) and numerically more TGD obtained PrEP from informal sources (aOR = 1.8; 95% CI = 0.9–3.5). Testing behaviour, condom use, and number of sexual partners were comparable between both groups. Socioeconomic disparities may constitute structural barriers for TGD people to access PrEP, leading to more informal and on-demand use. PrEP providers need to reduce access barriers for TGD PrEP users and provide information on safe PrEP use for this population.
Open AccessSimilar Sexual Behaviour yet Different Outcomes: Comparing Trans and Gender Diverse and Cis PrEP Users in Germany Based on the Outcomes of the PrApp Study
Little knowledge about pre-exposure prophylaxis (PrEP) use in trans and gender diverse (TGD) communities in Germany exists. The PrApp Study collected data on PrEP use and sexual behaviour among PrEP users in Germany. Descriptive methods and logistic regression were used to describe PrEP use among TGD and cis persons. A total of 4350 PrEP users in Germany were included, with 65 (1.5%) identified as TGD. Compared to cis participants, TGD participants were younger (median age 29 vs. 37 years) and more likely to have a lower income (adjusted odds ratio (aOR) = 4.4; 95% confidence interval (CI) = 2.4–8.2) and be born outside Germany (aOR = 2.5; 95% CI = 1.3–4.5). On-demand PrEP use was higher in TGD participants (aOR = 1.9; 95% CI = 1.0–3.5) and numerically more TGD obtained PrEP from informal sources (aOR = 1.8; 95% CI = 0.9–3.5). Testing behaviour, condom use, and number of sexual partners were comparable between both groups. Socioeconomic disparities may constitute structural barriers for TGD people to access PrEP, leading to more informal and on-demand use. PrEP providers need to reduce access barriers for TGD PrEP users and provide information on safe PrEP use for this population.
- 1 September 2020
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 36 (9) , 721-733
Rapid Uptake of Pre-Exposure Prophylaxis After Significant Price Reduction in Germany Highlights Importance of Pre-Exposure Prophylaxis Accessibility
Pre-Exposure Prophylaxis (PrEP) has been widely accepted as an effective method to prevent HIV infections, but high costs precluded a widespread use in Germany. A novel distribution pathway of tenofovir-disoproxil fumarate and emtricitabine Pre-Exposure Prophylaxis (PrEP) was implemented that reduced monthly PrEP costs by 16-fold in Germany. Over a period of six months, we recorded prescription data, demographics and sexual behaviour of PrEP users including self-reported sexual transmitted infections (STIs), alcohol and drug use. Within a month, prescriptions almost doubled from 585 to 1009 and reached a cumulative number of 6059 at the end of the 6-month observation period. Extrapolation of the data suggest an estimated maximal number of PrEP users of the order of 10000. PrEP users demonstrated to be a population of well-educated men(407/686) who have sex with men(629/686), median age 38(range:18-71) and of German descent(571/686). The majority used PrEP to compensate for risk of HIV infection when having condomless anal intercourse(372/686). At start of PrEP implementation, the majority perceived their own risk to acquire HIV as none to medium(78.6%; n=539), while only a subset(18.8%; n=129) considered themselves to be at high or very high risk for HIV infection. In contrast, within the last 6 months 28.4% of the PrEP users had an STI diagnosis and over 70% had condomless anal intercourse with more than 6 partners. Taken together, our data from PrEP implementation in Germany demonstrates a large uptake once it became affordable in individuals who wish to compensate for HIV risk when having condomless anal intercourse.
- 1 September 2020
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 36 (9) , 721-733
Rapid Uptake of Pre-Exposure Prophylaxis After Significant Price Reduction in Germany Highlights Importance of Pre-Exposure Prophylaxis Accessibility
Pre-Exposure Prophylaxis (PrEP) has been widely accepted as an effective method to prevent HIV infections, but high costs precluded a widespread use in Germany. A novel distribution pathway of tenofovir-disoproxil fumarate and emtricitabine Pre-Exposure Prophylaxis (PrEP) was implemented that reduced monthly PrEP costs by 16-fold in Germany. Over a period of six months, we recorded prescription data, demographics and sexual behaviour of PrEP users including self-reported sexual transmitted infections (STIs), alcohol and drug use. Within a month, prescriptions almost doubled from 585 to 1009 and reached a cumulative number of 6059 at the end of the 6-month observation period. Extrapolation of the data suggest an estimated maximal number of PrEP users of the order of 10000. PrEP users demonstrated to be a population of well-educated men(407/686) who have sex with men(629/686), median age 38(range:18-71) and of German descent(571/686). The majority used PrEP to compensate for risk of HIV infection when having condomless anal intercourse(372/686). At start of PrEP implementation, the majority perceived their own risk to acquire HIV as none to medium(78.6%; n=539), while only a subset(18.8%; n=129) considered themselves to be at high or very high risk for HIV infection. In contrast, within the last 6 months 28.4% of the PrEP users had an STI diagnosis and over 70% had condomless anal intercourse with more than 6 partners. Taken together, our data from PrEP implementation in Germany demonstrates a large uptake once it became affordable in individuals who wish to compensate for HIV risk when having condomless anal intercourse.
- Open Access
- 3 October 2019
- Published by Wiley in Journal of the International AIDS Society
- Vol. 22 (10) , e25395
Factors associated with the informal use of HIV pre‐exposure prophylaxis in Germany: a cross‐sectional study
Introduction: Until September 2019, pre‐exposure prophylaxis (PrEP) with tenofovir disoproxil/emtricitabine for HIV prevention was not covered by health insurance plans in Germany, and was only available through private prescriptions with self‐pay or through informal non‐prescription sources. The objective of this study was to investigate the proportion of informal PrEP use among PrEP users and to identify factors of public health relevance that might be associated with informal PrEP use.Methods: We conducted a cross‐sectional study recruiting PrEP users independent of their PrEP source. Clients from anonymous community testing checkpoints, users of three dating apps for men who have sex with men residing in Germany and users of a PrEP community website, were recruited to complete a short anonymous online survey. Participants were recruited between 24 July and 3 September 2018. The results were analysed using univariable and multivariable logistic regressions.Results: We recruited 2005 participants currently using PrEP. The median age was 38 years, and 80.3% of the participants identified themselves as male (missing: 19.1%). Overall, 71.6% obtained PrEP through medical services with a private prescription or a clinical trial, and 17.4% obtained PrEP through informal sources (missing: 11.0%). The most common informal sources were ordering online from another country (8.8%), travel abroad (3.6%), and friends (2.5%). Factors associated with informal PrEP use were on demand/intermittent dosing (adjusted OR: 3.5, 95% CI 2.5 to 5.0) and not receiving medical tests during PrEP use (adjusted OR: 3.2, 95% CI 2.0 to 5.2). In addition, informal PrEP users who did not take PrEP daily had a strongly increased risk of starting PrEP without prior medical tests (adjusted stratum‐specific OR = 31.7, 95% CI 4.6 to 219.5).Conclusions: Informal PrEP use was associated with a higher risk of not getting tested before and during PrEP use, which could lead to HIV infections resistant to tenofovir and emtricitabine if people with undiagnosed HIV use PrEP. Health insurance plans that cover PrEP and the accompanying routine tests could ensure adequate medical supervision of PrEP users and reduce barriers to PrEP use. Our findings strongly support the implementation of PrEP programmes in countries with similar patterns of informal PrEP use.
- 3 October 2019
- Published by Wiley in Journal of the International AIDS Society
- Vol. 22 (10) , e25395
Open AccessFactors associated with the informal use of HIV pre‐exposure prophylaxis in Germany: a cross‐sectional study
Introduction: Until September 2019, pre‐exposure prophylaxis (PrEP) with tenofovir disoproxil/emtricitabine for HIV prevention was not covered by health insurance plans in Germany, and was only available through private prescriptions with self‐pay or through informal non‐prescription sources. The objective of this study was to investigate the proportion of informal PrEP use among PrEP users and to identify factors of public health relevance that might be associated with informal PrEP use.Methods: We conducted a cross‐sectional study recruiting PrEP users independent of their PrEP source. Clients from anonymous community testing checkpoints, users of three dating apps for men who have sex with men residing in Germany and users of a PrEP community website, were recruited to complete a short anonymous online survey. Participants were recruited between 24 July and 3 September 2018. The results were analysed using univariable and multivariable logistic regressions.Results: We recruited 2005 participants currently using PrEP. The median age was 38 years, and 80.3% of the participants identified themselves as male (missing: 19.1%). Overall, 71.6% obtained PrEP through medical services with a private prescription or a clinical trial, and 17.4% obtained PrEP through informal sources (missing: 11.0%). The most common informal sources were ordering online from another country (8.8%), travel abroad (3.6%), and friends (2.5%). Factors associated with informal PrEP use were on demand/intermittent dosing (adjusted OR: 3.5, 95% CI 2.5 to 5.0) and not receiving medical tests during PrEP use (adjusted OR: 3.2, 95% CI 2.0 to 5.2). In addition, informal PrEP users who did not take PrEP daily had a strongly increased risk of starting PrEP without prior medical tests (adjusted stratum‐specific OR = 31.7, 95% CI 4.6 to 219.5).Conclusions: Informal PrEP use was associated with a higher risk of not getting tested before and during PrEP use, which could lead to HIV infections resistant to tenofovir and emtricitabine if people with undiagnosed HIV use PrEP. Health insurance plans that cover PrEP and the accompanying routine tests could ensure adequate medical supervision of PrEP users and reduce barriers to PrEP use. Our findings strongly support the implementation of PrEP programmes in countries with similar patterns of informal PrEP use.
- Open Access
- 4 March 2019
- Published by Springer Nature in Virology Journal
- Vol. 16 (1) , 1-7
Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o
HCV exhibits a high genetic diversity and is classified into 7 genotypes which are further divided into 86 confirmed subtypes. However, there are multiple isolates with unassigned subtypes. We aimed to amplify and characterize the full-length genome sequence of an HCV genotype 1 (HCV-1) divergent isolate (DE/17–0414) in Germany. The HCV infection was detected in an HIV-1-positive German female within an HCV/HIV-coinfection study using a commercially available antigen-antibody HCV ELISA kit and confirmed by an in-house quantitative real-time RT-PCR assay. Preliminary genotyping was done by sequencing and phylogenetic analysis on partial NS5B region. The full-length genome sequence was determined by consensus RT-PCR assays. Resistance-associated substitutions (RASs) were analyzed using the web-based tool Geno2pheno[HCV]. Partial NS5B region of the isolate DE/17–0414 showed more than 95% identity to 73–08460349-1 l and HCV_Fr_003 from France and QC316 from Canada. Full-length genome analysis of the DE/17–0414 strain showed 91.8% identity to QC316 but less than 79.6% to other HCV-1 strains. Phylogenetic analyses demonstrated that DE/17–0414, 73–08460349-1 l, HCV_Fr_003, and QC316 formed a separate subcluster within HCV-1. DE/17–0414 had a distinct 3 amino acids insertion at the N-terminal of hypervariable region 1 (HVR1) within viral envelope glycoprotein 2 (E2) and several potential antiviral RASs among the NS3 and NS5A genes. We identified and analyzed an HCV-1 divergent isolate derived from an HIV-1 coinfected individual in Germany, which will be assigned to a new HCV-subtype 1o. Our understanding of the origin and transmission dynamics of this new subtype 1o requires further assessments from patients worldwide.
- 4 March 2019
- Published by Springer Nature in Virology Journal
- Vol. 16 (1) , 1-7
Open AccessCharacterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o
HCV exhibits a high genetic diversity and is classified into 7 genotypes which are further divided into 86 confirmed subtypes. However, there are multiple isolates with unassigned subtypes. We aimed to amplify and characterize the full-length genome sequence of an HCV genotype 1 (HCV-1) divergent isolate (DE/17–0414) in Germany. The HCV infection was detected in an HIV-1-positive German female within an HCV/HIV-coinfection study using a commercially available antigen-antibody HCV ELISA kit and confirmed by an in-house quantitative real-time RT-PCR assay. Preliminary genotyping was done by sequencing and phylogenetic analysis on partial NS5B region. The full-length genome sequence was determined by consensus RT-PCR assays. Resistance-associated substitutions (RASs) were analyzed using the web-based tool Geno2pheno[HCV]. Partial NS5B region of the isolate DE/17–0414 showed more than 95% identity to 73–08460349-1 l and HCV_Fr_003 from France and QC316 from Canada. Full-length genome analysis of the DE/17–0414 strain showed 91.8% identity to QC316 but less than 79.6% to other HCV-1 strains. Phylogenetic analyses demonstrated that DE/17–0414, 73–08460349-1 l, HCV_Fr_003, and QC316 formed a separate subcluster within HCV-1. DE/17–0414 had a distinct 3 amino acids insertion at the N-terminal of hypervariable region 1 (HVR1) within viral envelope glycoprotein 2 (E2) and several potential antiviral RASs among the NS3 and NS5A genes. We identified and analyzed an HCV-1 divergent isolate derived from an HIV-1 coinfected individual in Germany, which will be assigned to a new HCV-subtype 1o. Our understanding of the origin and transmission dynamics of this new subtype 1o requires further assessments from patients worldwide.